

USSN 09/881,126

Amended Claims

- B¹
1. Cancelled
 - 5 2. Cancelled
 3. Cancelled
 - 10 4. Cancelled
 5. Cancelled
 6. Cancelled
 - 15 7. Cancelled
 8. Cancelled
 - 20 9. Cancelled
 10. Cancelled
 11. Cancelled
 - 25 12. Cancelled
 13. Cancelled
 - 30 14. Cancelled
 15. Cancelled
 16. Cancelled
 - 35 17. Cancelled
 18. Cancelled
 - 40 19. Cancelled
 20. Cancelled
 21. Cancelled
 - 45 22. Cancelled
 23. Cancelled

60,800A

24

USSN 09/881,126

24. Cancelled

25. Cancelled

5 26. Cancelled

27. Cancelled

28. Cancelled

10 29. Cancelled

30. Cancelled

15 31. Cancelled

32. (Original) A method for treatment of cancerous tumors in mammals, comprising administering a therapeutically effective quantity of a dendritic polymer-platinate compound to a mammal having a cancerous tumor.

20

33. (Original) The method of claim 32, wherein the dendritic polymer is a dendrimer.

34. (Original) The method of claim 32, wherein the dendritic polymer has anionic functional groups.

25

35. (Original) The method of claim 34, wherein the anionic groups are carboxylate groups.

36. (Original) The method of claim 32, wherein the dendritic polymer is a polyamidoamine dendrimer.

30

37. (Withdrawn) The method of claim 32, wherein the dendritic polymer is polypropylamine.

38. (Original) The method of claim 32, wherein the platinum containing compound is a compound comprising a central tetravalent platinum atom bonded to the nitrogen atom of two amine ligands, which may be the same or different, the amine ligands

35

USSN 09/881,126

being in cis confirmation with respect to each other and at least one of the remaining ligand sites is coupled to the dendritic polymer.

39. (Original) The method of claim 32, wherein the platinum containing compound is cisplatin.

5

40. (Withdrawn) The method of claim 32, wherein the dendritic polymer-platinate compound is administered parentally.

41. (Original) The method of claim 32, wherein the dendritic polymer-platinate compound is administered intravenously or intraperitoneally.

10

42. (Withdrawn) The method of claim 32, wherein the dendritic polymer-platinate compound is administered orally.

15

43. (Withdrawn) The method of claim 32, wherein the dendritic polymer-platinate compound is administered topically.

44. (Original) The method of claim 32, wherein the dendritic polymer-platinate compound is administered intraperitoneally.

20

45. (Original) The method of claim 32, wherein the molar ratio of cisplatin to dendritic polymer in the conjugate is from about 100:1 to about 1:1.

46. (Original) The method of claim 32, wherein the molar ratio of cisplatin to dendritic polymer in the conjugate is about 35:1.

25